Ulcerative Colitis Clinical Trials in New York, New York

18 studies are recruiting for ulcerative colitis in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

   Crohn's disease (CD) and Ulcerative colitis (UC) are 2 types of inflammatory bowel diseases which cause long-lasting, severe inflammation (redness, swelling) in the digestive tract. CD can affect any part of the digestive tract causing many different symptoms including belly pain, diarrhea, tiredne…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   New York Gastroenterology Associates - Upper East Side /ID# 281767, New York, New York

   Locations

   36 in total

   Run by

   AbbVie

   See if you can join NCT07697456 on ClinicalTrials.gov

2. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

   This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York

   Locations

   52 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03816345 on ClinicalTrials.gov

3. A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

   Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, and belly pain. The main aim of this study is to check for how many participants with UC and CD signs and symptoms disappear after 3.5 month…

   Stage

   Phase 4

   Ages

   18 to 80

   Site

   New York Gastroenterology Associates, New York, New York

   Locations

   101 in total

   Run by

   Takeda

   See if you can join NCT06581328 on ClinicalTrials.gov

4. A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

   This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 maintenance study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis (UC). Study details include: The study duration may be up to 286 weeks including: * 40…

   Stage

   Phase 3

   Ages

   16 to 80

   Site

   Weill Cornell Medicine - NewYork-Presbyterian Hospital - Site Number: 8400040, New York, New York

   Locations

   55 in total

   Run by

   Sanofi

   See if you can join NCT07185009 on ClinicalTrials.gov

5. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

   The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation …

   Stage

   Phase 3

   Ages

   18 to 70

   Site

   Icahn School of Medicine at Mount Sinai, New York, New York

   Locations

   187 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06937086 on ClinicalTrials.gov

6. A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

   This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary goal of the study is to assess the efficacy and safety of multiple interventions following intravenous (IV) induction and subcutaneous (SC) m…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Site 037, New York, New York

   Locations

   267 in total

   Run by

   Spyre Therapeutics, Inc.

   See if you can join NCT07012395 on ClinicalTrials.gov

7. A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

   The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits. Additional treatment may be available to participants via a Contin…

   Stage

   Phase 3

   Ages

   2 to 19

   Site

   Icahn School of Medicine at Mount Sinai, New York, New York

   Locations

   68 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT04844606 on ClinicalTrials.gov

8. A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis

   Adults between 18 and 80 years of age with ulcerative colitis can participate in this study. This is a study for people for whom previous treatment was not successful or who stopped previous treatment. The purpose of this study is to find out whether BI 3032950 helps people with ulcerative colitis.…

   Stage

   Phase 2

   Ages

   18 to 80

   Site

   Columbia University Medical Center, New York, New York

   Locations

   41 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT06636656 on ClinicalTrials.gov

9. An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

   This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis (UC). Study details include: The study duration may be up to 35 weeks wi…

   Stage

   Phase 3

   Ages

   16 to 80

   Site

   Manhattan Clinical Research, LLC - Site Number: 8400069, New York, New York

   Locations

   219 in total

   Run by

   Sanofi

   See if you can join NCT07184996 on ClinicalTrials.gov

10. A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

    The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative colitis (UC). Another aim is to learn about treatment with Vedolizumab alone after the double treatment. All participants wi…

    Stage

    Phase 4

    Ages

    18 to 65

    Site

    NYU Langone Health, New York, New York

    Locations

    46 in total

    Run by

    Takeda

    See if you can join NCT06095128 on ClinicalTrials.gov

11. Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

    The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ul…

    Stage

    Not phased

    Ages

    18 and older

    Site

    NYU Langone Health, New York, New York

    Locations

    24 in total

    Run by

    Mayo Clinic

    See if you can join NCT05230173 on ClinicalTrials.gov

12. BOOM-IBD2 Pivotal Clinical Trial

    Ulcerative colitis is a long-lasting condition that causes swelling and sores in the large intestine. This study tests whether a small device placed under the skin can help reduce bowel urgency in people with ulcerative colitis. The investigational device sends mild signals to a nerve near the tail…

    Stage

    Not phased

    Ages

    18 to 85

    Site

    Columbia University Irving Medical Center/New York Presbyterian Hospital, New York, New York

    Locations

    19 in total

    Run by

    Boomerang Medical

    See if you can join NCT06571669 on ClinicalTrials.gov

13. A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

    The main aim of this study is to learn how the body of a child or teenager with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD) processes vedolizumab (pharmacokinetics) given just under the skin subcutaneously (SC). The participants will be treated with vedolizumab for…

    Stage

    Phase 3

    Ages

    2 to 17

    Site

    New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York

    Locations

    54 in total

    Run by

    Takeda

    See if you can join NCT06100289 on ClinicalTrials.gov

14. A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

    The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC).

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    Pioneer Clinical Research NY, New York, New York

    Locations

    207 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06598943 on ClinicalTrials.gov

15. A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

    The main aim of this study is to learn about medical problems (adverse events) if vedolizumab subcutaneously (SC) is given to a child or teenager with UC or CD for a long time. Other aims are to understand if the long time use of vedolizumab SC has an impact on the time period until hospital visits…

    Stage

    Phase 3

    Ages

    2 to 17

    Site

    New York Presbyterian Hospital, New York, New York

    Locations

    54 in total

    Run by

    Takeda

    See if you can join NCT06405087 on ClinicalTrials.gov

16. A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis

    This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Ulcerative Colitis. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Ulcerative Colitis. The total study duration…

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    Investigational Site Number: 8400021, New York, New York

    Locations

    67 in total

    Run by

    Sanofi

    See if you can join NCT06975722 on ClinicalTrials.gov

17. Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)

    Chronic intestinal hypoxia and accompanying mucosal inflammation is a hallmark of ulcerative colitis (UC). Hyperbaric oxygen therapy (HBOT) involves breathing 100% oxygen under increased atmospheric pressure to increase tissue oxygenation. Two small prospective randomized controlled trials have dem…

    Stage

    Not phased

    Ages

    18 to 85

    Site

    Cornell University Medical Center, New York, New York

    Locations

    13 in total

    Run by

    Northwestern University

    See if you can join NCT05987852 on ClinicalTrials.gov

18. Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention

    The goal of this observational study is to assess the feasibility and effectiveness of a remote monitoring digital health system on adherence, clinical outcomes, and healthcare utilization in patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis, and inflammatory bowel disea…

    Stage

    Not phased

    Ages

    18 and older

    Site

    New York University, New York, New York

    Locations

    6 in total

    Run by

    Mercy Medical Center

    See if you can join NCT06750731 on ClinicalTrials.gov